Loading
Life sciences · Journal article
The Journal of Physiology · August 18, 2026
A consensus or society position rather than new primary data.
This is a prize lecture review surveying the development and clinical translation of patient-specific cardiac digital twins for arrhythmia substrate mapping and risk stratification. The work demonstrates that digital twins can inform clinical decisions in sudden cardiac death risk prediction, ventricular tachycardia ablation targeting, and atrial fibrillation ablation planning, but the authors acknowledge that clinical deployment remains limited by computational intensity and the need for scalability.
Journal article. Patients with ventricular disease, ventricular tachycardia, and atrial fibrillation (inferred from clinical applications described; not explicitly stated as study population). Johns Hopkins University (institutional affiliation of method developers); FDA-IDE trial mentioned but centres not specified.
Digital twins incorporating patient geometry, fibrosis, adiposity, inflammation and genotype can identify substrate determinants of arrhythmogenesis in ventricular and atrial disease Scar architecture, border-zone conduction slowing, repolarization gradients, adipose infiltration and genotype-specific remodelling govern re-entrant circuit emergence and stability Fibrosis distribution and driver anchoring shape atrial fibrillation dynamics in digital twin simulations
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that digital twin technology has progressed from experimental research to prospective clinical trials (FDA-IDE) for ventricular tachycardia ablation guidance and risk prediction, but widespread clinical deployment awaits resolution of computational scalability challenges. Current evidence supports consideration of digital twins within specialized centres but does not yet establish routine practice standards.
A published review of computational methods and their clinical translation, presenting expert consensus on the current state and future potential of digital twin technology in arrhythmia medicine, rather than reporting a primary research finding.
As stated by the source record.
Clinicians should recognize that digital twin technology has progressed from experimental research to prospective clinical trials (FDA-IDE) for ventricular tachycardia ablation guidance and risk prediction, but widespread clinical deployment awaits resolution of computational scalability challenges. Current evidence supports consideration of digital twins within specialized centres but does not yet establish routine practice standards.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Digital twins offer a way to translate rich patient data into individualized models that can be interrogated rather than merely described. In cardiac electrophysiology this approach has advanced to the point where the geometry, fibrosis, adiposity, inflammation and genotype of an individual heart can be incorporated into biophysically grounded simulations. This review accompanies The Physiological Society's annual Hodgkin-Huxley-Katz Award Lecture, presented to Dr. Natalia Trayanova in recognition of her contributions to computational cardiology and its clinical translation. It surveys the body of work developed by Dr. Trayanova and her group at Johns Hopkins University, charting the arc from the application of patient-specific heart digital twins to reveal substrate determinants of arrhythmogenesis to their translation to sudden cardiac death risk prediction and guidance of catheter ablation for ventricular tachycardia and atrial fibrillation (AF). Across ventricular disease these studies showed that scar architecture, border-zone conduction slowing, repolarization gradients, adipose infiltration and genotype-specific remodelling can govern the emergence and stability of re-entrant circuits. In the atria digital twins clarified how fibrosis distribution and driver anchoring shape AF dynamics. Taken together this body of work demonstrates that heart digital twins satisfy the operative medical criterion of informing clinical decisions that realize value, including non-invasive sudden cardiac death risk stratification, pre-procedural ventricular tachycardia (VT) ablation target prediction in a prospective Food and Drug Administration Investigational Device Exemption (FDA-IDE) clinical trial and personalized AF ablation planning. The major challenge ahead is to convert these validated but still computationally intensive technologies into scalable, continuously updated tools that can be deployed routinely in clinical care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.